Species	Number detected	(high; medium; low; no visible mould)

Epicoccum nigrum	15	(7,2,4,2)

Cladosporium cladosporioides	7	(3,3,1,0)

Aureobasidium pullulan	4	(1,1,2,0)

Cryptococcus flavescens	3	(1,2,0,0)

Alternaria alternata	2	(1,1,0,0)

Alternaria tenuissima	1	(0,0,1,0)

Aspergillus westerdijkiae	1	(0,0,1,0)

Candida parapsilosis	1	(0,1,0,0)

Cladosporium silenes	1	(0,0,0,1)

Cladosporium tenuissimum	1	(0,1,0,0)

Cladosporium uredinicola	1	(1,0,0,0)

Cochliobolus lunatus	1	(0,1,0,0)

Curvularia brachyspora	1	(0,1,0,0)

Curvularia trifolii	1	(0,1,0,0)

Leptosphaerulina australis	1	(0,1,0,0)

Paraphaeosphaeria sp	1	(1,0,0,0)

Penicillium fellutanum	1	(0,0,1,0)

Penicillium oxalicum	1	(0,1,0,0)

Penicillium polonicum	1	(0,0,0,1)

Penicillium spinulosum	1	(0,0,1,0)

Phoma herbarum	1	(0,0,1,0)

Rhodotorula slooffiae	1	(0,1,0,0)

Total	48

Species	Number detected

Epicoccum nigrum	15

Cladosporium cladosporioides	7

Aureobasidium pullulan	4

Cryptococcus flavescens	3

Alternaria alternata	2

Alternaria tenuissima	1

Aspergillus westerdijkiae	1

Candida parapsilosis	1

Cladosporium silenes	1

Cladosporium tenuissimum	1

Cladosporium uredinicola	1

Cochliobolus lunatus	1

Curvularia brachyspora	1

Curvularia trifolii	1

Leptosphaerulina australis	1

Paraphaeosphaeria sp	1

Penicillium fellutanum	1

Penicillium oxalicum	1

Penicillium polonicum	1

Penicillium spinulosum	1

Phoma herbarum	1

Rhodotorula slooffiae	1

Total	48


ROSA item	Symptom domain	Factor	Loading

1	The patient is able to remember events from a long time ago.	Cognition	Factor 1	0.6857

2	The patient is able to remember events of the recent past.	Cognition		0.7448

3	The patient is able to plan and carry out complex procedures.	Cognition		0.8526

4	The patient is able to make himself understood.	Communication		0.7138

5	The patient is able to communicate.	Communication		0.7966

6	The patient shows social competence.	Communication		0.7289

12	The patient is competent at everyday tasks.	Function/ADL		0.7791

13	The patient is attentive, shows interest in his surroundings.	Function/ADL		0.7284

14	The patient is independent.	Function/ADL		0.7849

15	The patient's quality of life is (very good/very poor).	Quality of life		0.4509

16	The burden for the caregiver is (very small/very large).	Caregiver burden		0.6183

7	The patient behaves aggressively.	Behavior	Factor 2	0.7309

8	The patient is restless.	Behavior		0.6248

9	The patient shows behavioral changes due to delusions.	Behavior		0.7397

10	The patient is insecure.	Behavior		0.5014

11	The patient's behavior is cooperative.	Behavior		0.6243

ROSA item

1	The patient is able to remember events from a long time ago.

2	The patient is able to remember events of the recent past.

3	The patient is able to plan and carry out complex procedures.

4	The patient is able to make himself understood.

5	The patient is able to communicate.

6	The patient shows social competence.

12	The patient is competent at everyday tasks.

13	The patient is attentive, shows interest in his surroundings.

14	The patient is independent.

15	The patient's quality of life is (very good/very poor).

16	The burden for the caregiver is (very small/very large).

7	The patient behaves aggressively.

8	The patient is restless.

9	The patient shows behavioral changes due to delusions.

10	The patient is insecure.

11	The patient's behavior is cooperative.

Symptom domain	Factor	Loading

Cognition	Factor 1	0.6857

Cognition		0.7448

Cognition		0.8526

Communication		0.7138

Communication		0.7966

Communication		0.7289

Function/ADL		0.7791

Function/ADL		0.7284

Function/ADL		0.7849

Quality of life		0.4509

Caregiver burden		0.6183

Behavior	Factor 2	0.7309

Behavior		0.6248

Behavior		0.7397

Behavior		0.5014

Behavior		0.6243


	Hill and Upchurch7	Alkema et al2

Type	Prescriptive	Descriptive

Data	Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964	All available data from vital registration systems, sample registration and surveillance systems, surveys and censuses from 195 countries since 1950.

Age ranges	Infant (<1 year), child (1–4 years) and under 5 (<5 years)

	Intended to reflect sex differentials in childhood mortality in the absence of substantial discrimination, but at relatively high levels of child mortality. Described by the authors as a mortality ‘standard’.	Intended to reflect actual sex ratios in mortality, regardless of the presence of gender bias. Country-specific sex ratios are presented; these results are based on the product of the expected sex ratio and a country-specific multiplier, which represents the relative advantage or disadvantage of girls to boys compared with other countries with similar total mortality rates.

Original estimates

Assessment of gender bias	Female advantage index (difference between the observed and expected female/male mortality ratios) for any given level of male mortality	Countries with outlying sex ratios. Excess female mortality expressed as the difference between the expected and estimated female mortality rates

	Hill and Upchurch7	Alkema et al2

Assessment of gender bias	Female advantage index (difference between the observed and expected female/male mortality ratios) for any given level of male mortality	Countries with outlying sex ratios. Excess female mortality expressed as the difference between the expected and estimated female mortality rates


Chemokine	Forward primer	Reverse primer	Product size (bp)

CCL-chr25s	5'-TTCTGCTGTTTTTGGTGTTCA	5'-GCTTTATCCAGTCCTCATCTGG	216

CCL-chr24a	5'-TACTTCTCAGCTTCCTTGTGGAGA	5'-CTCATCGTCTTCGTCTTCATTGTT	250

CXL-chr24a	5'-AGGTTGGAGCAGTACCGACAA	5'-CCTCCCCTCTACACGTTACCC	245

CCL-chr24c	5'-ATGCGTCTGTCCTCAGCTTT	5'-GCTGTCGGATCTATGCAGTG	284

CCL-chr24m	5'-AGGAGTTTGGCTGTTGCACT	5'-CCTCCTCACCCACAGTTGTC	219

CCL-chr20d	5'-CAGACAAGTGCTGCTTTTCG	5'-GAGCTGGCCTCTGTGTCTTT	209

CCL-chr20g	5'-CGCTTTCTGCTCAGTTGTTG	5'-TCAGTCTCCGAACCCATTTC	215

scybaa	5'-TGCAGATGCACAAGAAAAGG	5'-GGCTTCAAACGTCCTGTGTT	225

cxcl12aa	5'-TTCATGCACCGATTTCCAAC	5'-TGTTGATGGCGTTCTTCAGG	222

CXCL-chr13a	5'-CAACATGTCCCAAAGACCTG	5'-TTACCTGTTCCAACATTTCATTAGA	201

CXCL-chr13c	5'-ACTGCCCATCCAGCAGTTAC	5'-TCCTGCCTTCGATGATCTTT	200

CXCL-chr13d	5'-TTGTTTTTGGAGTCAGCATCA	5'-AGTGTGTTCTGGGGTTCAGG	222

CCL-chr11a	5'-CCAGCATCGCACAAGGTTAC	5'-GCCTGGACCCAGTCACTTCT	208

CCL-chr11b	5'-ATGCAGCGAGATGTTCAGTG	5'-GGAATTCACAACAGCGACCT	282

CCL-chr10a	5'-CGATGATGCAGTGGATTGTT	5'-TTTCCTGGGTCGTTTTTGTG	235

CCL-chr10b	5'-TACTGTGCATCGCCTTCAGC	5'-TAGACGAGCCATTCGCTTCA	233

ccl1a	5'-GGCACGAGATGGAGTTCAGA	5'-GCCGTCTGTATCCGTGATTT	329

CCL-chr5a	5'-ACGGTCAGCCCAAGAGTCAT	5'-GAGCATGACAGCGTCTCTCG	229

CCL-chr5b	5-CCATAACTCTCCTGCTCATCG	5'-GCGCAGAGTTTCTTGTCCTT	202

CXCL-chr5c	5'-AAGTGCGTGCCTGATAAACC	5'-CACATCAACTGCCTGAATGG	229

CXCL-chr5d	5'-TGTTACTGCTCTGCTTCTTGTCA	5'-CATCGTTTTCCAGCTCCATT	204

CXCL-chr1c	5'-TACGTCCAGCAGGGAGAAGT	5'-CCCTGCTGTTTTTGTGGATT	218

CCL-chrUi	5'-GACTTCTGGCCGTCACATTC	5'-AGCTGAGGGTCCACACAGAG	202

β-actin	5'-TGTTCGAGACCTTCAACACC	5'-TGAAGGTGGTCTCGTGGATA	471


Gender	Male

Age	10 y

Diagnosis	Oppositional defiant disorder

Intellligence quotient (IQ)	59

NCBRF total score

 Baseline	33

 Endpoint	31

Time point	Risperidone dose (mg/day)	Dyskinesia score*

 Baseline	0.000	3

 Week 1	0.343	3

 Week 2	1.200	3

 Week 3	1.814	3

 Week 4	1.900	3

 Week 8	1.784	---

 Week 12	1.300	4

 Week 16	1.300	7

 Week 20	1.300	7

 Week 24	1.300	1

 Week 36	1.300	2

 Week 48	1.300	0


	Screening	Pretreatment	Discharge	End of Intervention	Follow-up

Study visits		T0	T1	T2	T3

Written informed consent	X

Screening questions	X

BDI-II	X		X	X	X

GAD-7		X	X		X

PHQ-9		X	X		X

RSE		X	X		X

EUROHIS-QOL 8		X	X		X

DAS		X	X		X

CTQ		X

WAI		X	X		X

OPD-SQ		X

HAQ			X

Satisfaction with intervention			X	X

Utilization of other treatment					X

BADO		X	X

Willingness to pay				X

Adverse events		continuously	X	X


Goal	I have set this goal (N)	Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)	I will continue to make these changes after the intervention

Very likely (%)	Likely (%)	Not sure (%)

Improving diet	346	99	83	15	2

Increasing physical activity	306	96	67	32	1

Reducing smoking/tobacco	51	76	82	18	–

Reducing alcohol consumption	62	98	56	34	10

Goal	I have set this goal (N)	Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)	I will continue to make these changes after the intervention

Very likely (%)

Improving diet	346	99	83

Increasing physical activity	306	96	67

Reducing smoking/tobacco	51	76	82

Reducing alcohol consumption	62	98	56

I will continue to make these changes after the intervention

Likely (%)	Not sure (%)

15	2

32	1

18	–

34	10


Isoform	Substrate	Metabolite	Ranges of substrate concentrations in the incubations, μM	Fluorescence detection excitation/emission

CYP1A	ER	resorufin	0.1–12.0	560/586 nm

CYP2A	coumarin	hydroxycoumarin	2.5–300.0	338/458 nm

CYP3A	BFC	HFC	0.4–120.0	410/538 nm


SNPs	No. of every SNP type	Caused by	Total No. of transition and transversion

A/G	28769	Transition	53208

C/T	24439

A/C	6832	Transversion	30667

G/T	12016

A/T	4315

G/C	7504

SNPs	No. of every SNP type	Caused by	Total No. of transition and transversion

A/G	28769	Transition	53208

C/T	24439

A/C	6832	Transversio	306

G/T	1

SNPs	No. of every SNP type	Caused by	Total No. of transition and transversion

	2016	n	67

A/T	4315

G/C	7504


Term	Definition

SP-trEMBL	Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.

Integr8_263	Sequence dataset containing 913,094 sequences from 263 completed genomes listed in the Integr8 genome database.

Pfam_struc	Pfam-A family containing a PDB structure that has not yet been classified into the CATH domain database.

NewFam	Protein families generated in the Gene3D

Term

SP-trEMBL

Integr8_263

Pfam_struc

NewFam

Definition

Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.

Sequence dataset containing 913,094 sequences from 263 completed genomes listed in the Integr8 genome database.

Pfam-A family containing a PDB structure that has not yet been classified into the CATH domain database.

Protein families generated in the Gene3D


	EDA group (n = 68)	Opioid group (n = 98)	p-value

Age (years)	59.3 ± 16.0	59.9 ± 15.3	n.s.

Male gender (%)	58.8	66.3	n.s.

Hospital stay (days)	9.8 ± 5.7	11.1 ± 9.4	n.s.

Pre-existing pain therapy (%)	8.8	9.2	n.s.

Dismission with oral opioid (%)	73.5	76.5	n.s.

Opiod dose after dismission (mg)	27.7 ± 15.2	28.3 ± 16.4	n.s.

Time to first dejection (days)	3.5 ± 1.8	3.9 ± 2.2	n.s.

EDA duration (days)	4.5 ± 2.0	-


	PD-L1 Expression	*P value

	+	-

E-Cadherin

Down-regulated (≤70 %)	9 (47)a	10 (53)	0.039

Positive (> 70 %)	10 (21)	38 (79)

Vimentin

Up-regulated (> 5 %)	10 (53)	9 (47)	0.014


Reference	Numbers studied	Type of controls	Susceptibility	Severity	Ethnicity

	Cancer	Controls

Hefler LA et al, 2005 [58]	269	227	Women visiting outpatient dept for various reasons	No association	No association	Caucasian

Our study	691	420	Women with normal mammograms from screening population	No association	No association	British Caucasian

Reference	Numbers studied	Type of controls	Susceptibility	Severity	Ethnicity

	Cancer	Controls

Our study	691	420	Women with normal mammograms from screening population	No association	No association	British Caucasian


Simulation Results	Yeast 5	Yeast 6

Auxotroph-inducing genes	92	93

Correct auxotrophy predictions	57	64

Mutant incorrectly predicted to be viable in minimal medium	32	26

Mutant incorrectly predicted to be inviable in supplemented medium	3	3


	Group C	Group B

Subgroups	Normotensive(n = 41)	Treated HT(n = 7)	Untreated HT(n = 7)	Normotensive(n = 41)	Treated HT(n = 7)	Untreated HT(n = 4)

Additional Propofol	22 (55 %)	2 (29 %)	4 (57 %)	24 (59 %)	0 (0 %)	1 (25 %)

Adverse Events

HR < 50 bpm	3 (8 %)	1 (14 %)	2 (29 %)	3 (7 %)	2 (29 %)	0 (0 %)

	Group C	Group B

Subgroups	Normotensive(n = 41)	Treated HT(n = 7)	Untreated HT(n = 7)	Normotensive(n = 41)	Treated HT(n = 7)	Untreated HT(n = 4)

SBP < 70 mmHg	8 (20 %)	2 (29 %)	0 (0 %)	9 (22 %)	2 (29 %)	0 (0 %)

Use of Ephedrine	8 (20 %)	2 (29 %)	0 (0 %)	4 (10 %)	2 (29 %)	0 (0 %)


Subgroups	n	Cases of the grade of tracheal intubation conditions (1/2/3/4)	Cases of the anaphylaxis score (0/1/2/3)	Duration of surgery (min)

Group 1	39	29/10/0/0	32/7/0/0	69 ± 34

Group 2	37	29/8/0/0	35/2/0/0	75 ± 40

Group 3	39	37/2/0/0	35/2/2/0	76 ± 40

Group 4	40	31/9/0/0	38/2/0/0	67 ± 33

Subgroups	n	Cases of the grade of tracheal intubation conditions (1/2/3/4)	Cases of the anaphylaxis score (0/1/2/3)	Duration of surgery (min)

Group 2	37	29/8/0/0	35/2/0/0	75 ± 40

Group 3	39	37/2/0/0	35/2/2/0	76 ± 40

Group 4	40	31/9/0/0	38/2/0/0	67 ± 33


Demographic Characteristics	TOTAL	%

Female	15	75%

Race

 White	15	75%

 Black	4	20%

 Asian	1	5%

Age

 ≤ 30	4	20%

 31–40	0	0%

 41–50	8	40%

 51–60	5	25%

 61–70	2	10%

 ≥ 71	1	5%

Education

 Some or graduate of high school	10	50%

 Some college	5	25%

 College graduate	1	5%

 Post graduate education	4	20%

Have access to e-mail & Internet	19	95%

Location of frequent access to e-mail & Internet

 Home	9	45%

 Library	4	20%

 Multiple sites	5	25%

Demographic Characteristics	TOTAL	%

Home	9	45%

Library	4	20%

Multiple sites	5	25%


MiR	Parametric p-value	FDR	Permutation p-value	Geom mean of intensities in class 1	Geom mean of intensities in class 2	Geom mean of intensities in class 3	Geom mean of intensities in class 4

hsa-miR-204-4373094	0.00004	0.02784	< 1e-07	15.74986	11.70222	14.82001	6.94659

hsa-miR-30aSTAR-4373062	0.00035	0.11658	0.00010	7.67985	6.27768	7.25131	6.95430

MiR	Parametric p-value	FDR	Permutation p-value	Geom mean of intensities in class 1	Geom mean of intensities in class 2	Geom mean of intensities in class 3	Geom mean of intensities in class 4

hsa-miR-30aSTAR-4373062	0.00035	0.11658	0.00010	7.67985	6.27768	7.25131	6.95430


	Count	%

He/she used to work but is currently unemployed	0	0.00

He/she never worked and neither does now	0	0.00

Clerk (civil or private)	338	63.41

Free professional (tradesman, craftsman)	62	11.63

Doctor, lawyer, engineer, priest, teacher, etc.	75	14.07

Student (college or university)	12	2.25

Blue collar worker (construction worker, farmer)	26	4.88

Housewife	20	3.75

Total	533	100.00

	Count	%

Student (college or university)	12	2.25

Blue collar worker (construction worker, farmer)	26	4.88

Housewife	20	3.75

Total	533	100.00


Children

Parameter

PT (seconds)

Before

After

P value

CT (seconds)

Before

After

P value

PT concentration (%)

Before

After

P value

INR

Before

After

PT/INR

Before

After

P value

PTT (seconds)

Before

After


 	Hazard ratio	95% confidence interval	p value

Mean age∗	1.026	1.013–1.040	<0.001

Country of birth, Nordic country	1.446	0.980–2.135	0.063

Chronic physical disease	1.025	0.789–1.332	0.851

Work for the last 3 yrs	0.781	0.588–1.038	0.088

Lifetime history of substance abuse (>1 yr)

Binge drinking	1.001	0.768–1.304	0.995

Heroin∗	1.737	1.261–2.393	0.001

Other opioids	0.938	0.655–1.345	0.729

Sedatives∗	1.404	1.026-1.923	0.034

Amphetamine∗	0.684	0.491–0.953	0.025

Cannabis	1.067	0.791–1.439	0.670

Injection drug use∗	1.430	1.013–2.018	0.042

Mean number of substances used, last 30 days	1.040	0.922–1.172	0.524

Lifetime history of psychiatric problems

Hospitalization	1.099	0.784–1.541	0.583

Suicide attempt	1.136	0.839–1.539	0.410

	Hazard ratio	95% confidence interval	p value

Heroin∗	1.737	1.261–2.393	0.001

Other opioids	0.938	0.655–1.345	0.729

Sedatives∗	1.404	1.026-1.923	0.034

Amphetamine∗	0.684	0.491–0.953	0.025

Cannabis	1.067	0.791–1.439	0.670

Injection drug use∗	1.430	1.013–2.018	0.042

Mean number of substances used, last 30 days	1.040	0.922–1.172	0.524

Lifetime history of psychiatric problems

Hospitalization	1.099	0.784–1.541	0.583

Suicide attempt	1.136	0.839–1.539	0.410


Cardiometabolic disease outcome	Amount quintile 1	Amount quintile 2	Amount quintile 3	Amount quintile 4	Amount quintile 5	P-trend

Odds ratio (95% CI)


Cluster ID	No. of sequences	Percentage of effective siRNAs (%)

C1	1	94


	No. Patients (%)	Methylation (%)	P

All patients	50 (100)	31( 62)


Method	Resnik	Relevance	Wang	NETSIM	NETSIM2

75%	0.42	1.03	0.91	1.19	3.75


	Without DM (n = 334)	With DM (n = 122)

Characteristics	VAT T1 (n = 111)	VAT T2 (n = 112)	VAT T3 (n = 111)	VAT T1 (n = 40)	VAT T2 (n = 41)	VAT T3 (n = 41)


Grenoble (n = 232)	Montpellier (n = 128)	Paris (n = 272)	Total (n = 632)


Factor	Score

Vascular invasion

 no	0

 yes	2.6

BCLC stage

 0-A	0

 B-C	1.3

MiR-145

 negative	0

 positive	1.3

MiR-31

 negative	0

 positive	1.7

MiR-92a

 negative	0

 positive	1


Time for data collection	Participants in the interviews

May–September 2013	Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24

May–September 2014	Unit managers, n = 5Officials, n = 16